Neurocrine Biosciences
Neurocrine Biosciences, Inc.
12780 El Camino Real
San Diego, CA 92130
Phone: (858) 617-7600Website: https://www.neurocrine.com/Careers: www.neurocrine.com/work-with-us
Latest news
- FDA Approves Crenessity (crinecerfont) for the Treatment of Children and Adults with Classic Congenital Adrenal Hyperplasia
15 December 2024 - Neurocrine Biosciences Announces U.S. FDA Approval of Ingrezza Sprinkle (valbenazine) Capsules
30 April 2024 - New INGREZZA Capsules Data Demonstrates Early and Sustained Improvements in Chorea Associated With Huntington's Disease
29 August 2023 - Neurocrine Biosciences Announces FDA Approval of Ingrezza (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease
18 August 2023 - FDA Approves Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes
27 April 2020 - Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
10 July 2019 - Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data
14 February 2018 - Neurocrine Announces FDA Approval of Ingrezza (valbenazine) as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)
11 April 2017 - Neurocrine Provides Update on FDA Advisory Committee for Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia
5 January 2017 - Neurocrine Announces FDA Advisory Committee Meeting to Review Ingrezza (valbenazine) NDA for the Treatment of Tardive Dyskinesia
29 November 2016
Drugs Associated with Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Crenessity
Generic name: crinecerfont Drug class: adrenal corticosteroid inhibitors |
||
|
Ingrezza
Generic name: valbenazine Drug class: VMAT2 inhibitors |
19 reviews | 6.1 / 10 |
|
Ingrezza Sprinkle
Generic name: valbenazine Drug class: VMAT2 inhibitors |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||